206 related articles for article (PubMed ID: 29845393)
1. The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer.
Yousef AM; Zawiah M; Al-Yacoub S; Kadi T; Tantawi DA; Al-Ramadhani H
Cancer Chemother Pharmacol; 2018 Aug; 82(2):237-243. PubMed ID: 29845393
[TBL] [Abstract][Full Text] [Related]
2. Investigation of
Cevik M; Namal E; Sener ND; Koksal UI; Cagatay P; Deliorman G; Ciftci C; Karaalp A; Susleyici B
Per Med; 2022 Sep; 19(5):435-444. PubMed ID: 35880438
[TBL] [Abstract][Full Text] [Related]
3. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
Falvella FS; Cheli S; Martinetti A; Mazzali C; Iacovelli R; Maggi C; Gariboldi M; Pierotti MA; Di Bartolomeo M; Sottotetti E; Mennitto R; Bossi I; de Braud F; Clementi E; Pietrantonio F
Br J Clin Pharmacol; 2015 Sep; 80(3):581-8. PubMed ID: 25782327
[TBL] [Abstract][Full Text] [Related]
4. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.
Etienne-Grimaldi MC; Milano G; Maindrault-Goebel F; Chibaudel B; Formento JL; Francoual M; Lledo G; André T; Mabro M; Mineur L; Flesch M; Carola E; de Gramont A
Br J Clin Pharmacol; 2010 Jan; 69(1):58-66. PubMed ID: 20078613
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms of MTHFR C677T and A1298C associated with survival in patients with colorectal cancer treated with 5-fluorouracil-based chemotherapy.
Yeh CC; Lai CY; Chang SN; Hsieh LL; Tang R; Sung FC; Lin YK
Int J Clin Oncol; 2017 Jun; 22(3):484-493. PubMed ID: 28044213
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms of the folate metabolizing enzymes: Association with SLE susceptibility and in silico analysis.
Salimi S; Keshavarzi F; Mohammadpour-Gharehbagh A; Moodi M; Mousavi M; Karimian M; Sandoughi M
Gene; 2017 Dec; 637():161-172. PubMed ID: 28943344
[TBL] [Abstract][Full Text] [Related]
7. DPYD gene polymorphisms are associated with risk and chemotherapy prognosis in pediatric patients with acute lymphoblastic leukemia.
Zhao XQ; Cao WJ; Yang HP; Yang XW; Tang P; Sun L; Gao X
Tumour Biol; 2016 Aug; 37(8):10393-402. PubMed ID: 26846104
[TBL] [Abstract][Full Text] [Related]
8. Early disease relapse in a patient with colorectal cancer who harbors genetic variants of DPYD, TYMS, MTHFR and DHFR after treatment with 5-fluorouracil-based chemotherapy.
Zawiah M; Yousef AM; Kadi T; Yousef M; Majdalawi K; Al-Yacoub S; Al-Hiary R; Tantawi D; Mukred R; Ajaj AR
Drug Metab Pers Ther; 2018 Dec; 33(4):201-205. PubMed ID: 30207288
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms of folate metabolism-related genes and survival of patients with colorectal cancer in the Korean population.
Jang MJ; Kim JW; Jeon YJ; Chong SY; Hong SP; Hwang SG; Oh D; Cho YK; Ji YG; Kim NK
Gene; 2014 Jan; 533(2):558-64. PubMed ID: 24100087
[TBL] [Abstract][Full Text] [Related]
10. Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy.
Fernández-Peralta AM; Daimiel L; Nejda N; Iglesias D; Medina Arana V; González-Aguilera JJ
Int J Colorectal Dis; 2010 Feb; 25(2):141-51. PubMed ID: 19669769
[TBL] [Abstract][Full Text] [Related]
11. Functional polymorphisms of folate-metabolizing enzymes in relation to homocysteine concentrations in systemic lupus erythematosus.
Summers CM; Cucchiara AJ; Nackos E; Hammons AL; Mohr E; Whitehead AS; Von Feldt JM
J Rheumatol; 2008 Nov; 35(11):2179-86. PubMed ID: 18785313
[TBL] [Abstract][Full Text] [Related]
12. DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.
Nahid NA; Apu MNH; Islam MR; Shabnaz S; Chowdhury SM; Ahmed MU; Nahar Z; Islam MS; Islam MS; Hasnat A
Cancer Chemother Pharmacol; 2018 Jan; 81(1):119-129. PubMed ID: 29134491
[TBL] [Abstract][Full Text] [Related]
13. 5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX.
Onesti CE; Botticelli A; La Torre M; Borro M; Gentile G; Romiti A; Lionetto L; Petremolo A; Occhipinti M; Roberto M; Falcone R; Simmaco M; Marchetti P; Mazzuca F
Anticancer Drugs; 2017 Mar; 28(3):322-326. PubMed ID: 27845948
[TBL] [Abstract][Full Text] [Related]
14. Low folate status, and MTHFR 677C > T and MTR 2756A > G polymorphisms associated with colorectal cancer risk in Thais: a case-control study.
Panprathip P; Petmitr S; Tungtrongchitr R; Kaewkungwal J; Kwanbunjan K
Nutr Res; 2019 Dec; 72():80-91. PubMed ID: 31740010
[TBL] [Abstract][Full Text] [Related]
15. The Roles of
Wang Y; Du M; Vallis J; Shariati M; Parfrey PS; Mclaughlin JR; Wang PP; Zhu Y
Nutrients; 2022 Nov; 14(21):. PubMed ID: 36364857
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Thymidylate Synthase and Methylenetetrahydrofolate Reductase Genotypes on Sensitivity to 5-Fluorouracil Treatment in Colorectal Cancer Cells.
Naghibalhossaini F; Shefaghat M; Mansouri A; Jaberi H; Tatar M; Eftekhar E
Acta Med Iran; 2017 Dec; 55(12):751-758. PubMed ID: 29373881
[TBL] [Abstract][Full Text] [Related]
17. Risk of colorectal cancer associated with the C677T polymorphism in 5,10-methylenetetrahydrofolate reductase in Portuguese patients depends on the intake of methyl-donor nutrients.
Guerreiro CS; Carmona B; Gonçalves S; Carolino E; Fidalgo P; Brito M; Leitão CN; Cravo M
Am J Clin Nutr; 2008 Nov; 88(5):1413-8. PubMed ID: 18996879
[TBL] [Abstract][Full Text] [Related]
18. Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma.
Puerta-García E; Urbano-Pérez D; Carrasco-Campos MI; Pérez-Ramírez C; Segura-Pérez A; Calleja-Hernández ; Cañadas-Garre M
Surg Oncol; 2020 Dec; 35():388-398. PubMed ID: 33035787
[TBL] [Abstract][Full Text] [Related]
19. The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
Maharjan AS; McMillin GA; Patel GK; Awan S; Taylor WR; Pai S; Frankel AE; Nelson C; Wang B; Hosein PJ; Singh AP; Khushman M
Clin Colorectal Cancer; 2019 Sep; 18(3):e280-e286. PubMed ID: 31160238
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
